Related Experiment Videos

Effect of fluid intake on the outcome of constipation in children: PEG 4000 versus lactulose

Sun Hwan Bae1, Jae Sung Son, Ran Lee

  • 1Department of Pediatrics, Konkuk University, School of Medicine, Seoul, South Korea. baedori@hanafos.com

Insights

Increased fluid intake improves bowel movements and stool consistency in children with chronic constipation treated with polyethylene glycol 4000 (PEG 4000). Lactulose treatment showed no significant benefit from increased fluids.

Area of Science:

  • Pediatric Gastroenterology
  • Clinical Nutrition
  • Pharmacology

Background:

  • Chronic constipation is a common pediatric issue.
  • Osmotic laxatives like PEG 4000 and lactulose are frequently used.
  • The role of fluid intake in treatment efficacy is not fully understood.

Purpose of the Study:

  • To investigate the impact of fluid intake on the effectiveness of PEG 4000 and lactulose in treating pediatric chronic constipation.
  • To compare treatment outcomes under conditions of good versus poor fluid intake.

Main Methods:

  • Retrospective review of 27 children with chronic constipation on stable laxative therapy.
  • Patients were assessed during periods of high and low fluid intake using validated scoring systems for bowel movements and stool consistency.
  • Statistical analysis was performed using the Wilcoxon signed-rank test.

Main Results:

  • Children on PEG 4000 showed significantly improved bowel movement scores (P = 0.009) and stool consistency (P = 0.002) with higher fluid intake.
  • No statistically significant difference in outcomes was observed for children treated with lactulose.
  • The study highlights a positive correlation between fluid intake and PEG 4000 efficacy.

Conclusions:

  • Additional fluid intake provides significant benefits for children with chronic constipation already receiving PEG 4000.
  • Fluid supplementation may not enhance the efficacy of lactulose in this patient population.
  • Optimizing hydration is a crucial adjunct therapy for PEG 4000 treatment in pediatric constipation.
Abstract

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives01:22

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...